

Pratima Sharma, MD, MS.  
Assistant Professor  
Division of Gastroenterology  
Department of Medicine  
University of Michigan  
3912 Taubman Center, SPC 5362  
1500 E. Medical Center Drive  
Ann Arbor, MI 48109  
734-936-4780  
[pratimas@med.umich.edu](mailto:pratimas@med.umich.edu)

## Education and Training

9/1987-12/1992 University College of Medical Sciences, University of Delhi, Delhi, India  
M.D with High Distinction in Anatomy

1/1993-6/1993 Junior Resident, Ophthalmology, Guru Teg Bahadur Hospital, Delhi, India

7/1993-5/1994 PGY-1, ENT, Lady Hardinge Medical College, New Delhi, India

8/1994-10/1994 Research fellow, Division of Nephrology, Long Island Jewish Medical Center,  
New Hyde Park, New York

11/1994-6/1996 Research Fellow, Division of Nephrology, Long Island Jewish Medical Center,  
New Hyde Park, New York

7/1996-6/1999 Resident, Categorical Internal Medicine Program, Bronx Lebanon Hospital  
Center, Bronx, New York

7/2002-6/2003 Clinical Fellow, Advanced Hepatology and Liver Transplantation Fellowship,  
Mayo Clinic, Scottsdale, Arizona

7/2005-6/2008 Gastroenterology Fellow, University of Michigan, Ann Arbor, Michigan

9/2005-5/2007 University of Michigan, School of Public Health, Ann Arbor, Michigan  
M.S (Clinical Research Design and Statistical Analysis)

## Certification and Licensure

Medical Licensure: Arizona 1999 to 2005  
Georgia 2003 to 2009  
Michigan 2005 to present (expires in 2018)

Certification: American Board of Internal Medicine 8/1999  
OPTN certified Primary Liver Transplant Physician for Emory Transplant Center  
(1/2004 to 6/2005)

OPTN certified liver transplant physician for University of Michigan transplant center  
ABIM-Gastroenterology Boards (11/2008)  
ABIM-Transplant Hepatology Boards (11/2010)

## **Academic, Administrative and Clinical Appointments**

### Academic Appointments

2003-2004	Clinical Instructor, Emory University School of Medicine, Atlanta, GA
2004-2005	Assistant Professor, Emory University School of Medicine, Atlanta, GA
7/2008-6/2011	Lecturer, University of Michigan, Ann Arbor, MI
7/2011- 8/2017	Assistant Professor, University of Michigan, Ann Arbor, MI
9/2017- Present	Associate Professor with Tenure, University of Michigan, Ann Arbor, MI

### Administrative Appointments:

1/2004-6/2005	Medical Director, Liver Transplant, Emory University Hospital, Atlanta, GA
---------------	--

### Clinical Appointments:

1999-2002	Staff Physician, Winslow Memorial Hospital, Winslow, AZ
8/2003-12/2003	Staff Hospitalist, Emory Healthcare, Emory University, Atlanta, GA

## **Research Interests**

1. Liver transplantation outcomes pertaining to liver allocation, waiting list mortality, post transplant survival and post liver transplant renal failure
2. Cirrhosis of liver and complications of portal hypertension
3. Renal dysfunction before and after liver transplantation
4. Viral hepatitis, complications of portal hypertension and hepatocellular carcinoma

## **Grants**

### Present

Title: Burden of hospitalization among liver transplant recipients  
Funding Agency: R03-National Institute of Diabetes Digestive and Kidney Diseases  
Start Dates: 4/1/2015 – 3/31/2018  
Role: Principal Investigator  
Effort: 0% concomitant with KO8  
Total cost: \$ 154,704

Title: Transplant Outcomes Using Generic and Brand Name Immunosuppressants: studying medications used by people who have received kidney and liver transplants (PI: Alan Leichtman, MD)  
Funding Agency: U01 FD005274-01- Food and Drug Administration  
Start Dates: 10/1/14-8/31/17  
Role: Co-investigator  
Effort: 5%

Cost: \$117,368

Title: Biomarkers of Chronic Kidney Disease among liver transplant recipients  
Funding agency: University of Michigan George M O'Brien Renal Core Center  
Start Date: 9/2015-8/2016  
Role: Principal Investigator  
Effort: 0%  
Cost: \$5000

Title: Improving Renal Outcomes among Liver Transplant Recipients  
Funding agency: MCUBE, University of Michigan  
Start date: 4/1/16-12/31/17  
Role: Principal Investigator  
Effort: 0%  
Cost: \$15,000

Title: Biomarkers of Chronic Kidney Disease among liver transplant recipients  
Funding agency: University of Michigan George M O'Brien Renal Core Center  
Start Date: 9/2016-8/2017  
Role: Principal Investigator  
Effort: 0%  
Cost: \$5000

Title: Unbiased glycoproteomic approach for risk prediction for chronic kidney disease progression among liver transplant recipients: Pilot funding  
Funding agency: University of Michigan George M O'Brien Renal Core Center  
Start Date: 7/2017-6/2018  
Role: Principal Investigator  
Effort: 0%  
Cost: \$35,000

Title: A multi-center, randomized, placebo controlled, double-blind study to confirm efficacy and safety of terlipressin in subjects to confirm efficacy and safety of terlipressin in subjects with hepatorenal syndrome type 1 (THE CONFIRM STUDY)  
Funding Agency: Mallinckrodt Pharmaceuticals  
Start Date: 1/1/17-12/31/19  
Role: Site Principal Investigator  
Effort: 5%

#### Past

Title: T32, Institutional training grant (PI: Chung Owyang, MD)  
Funding Agency: National Institute of Diabetes Digestive and Kidney Diseases  
Dates: 7/2005 – 6/2007  
Role: Trainee  
Title: Serum Creatinine is Over-weighted in Model for End Stage Liver Disease (MELD) Formula (PI: David E. Schteingart, MD)

Funding Agency: K30, HL04108, Curriculum Development Award  
Funding Source: National Institute of Health  
Dates: 9/1/2005- 7/31/07  
Role: Trainee

Title: Scientific Registry of Transplant Recipients (PI: Robert M Merion, MD)  
Funding agency: Health Resources and Services Administration  
Dates: 9/1/2009-12/28/10  
Role: Co-Investigator  
Effort: 10%  
Total Cost: \$5,218,630

Title: Re-weighting of the Model for End-Stage Liver Disease (MELD): Effects on survival benefit and the burden of renal disease  
Funding Agency: American Society of Transplantation  
Dates: 7/1/2008-6/30/2010  
Role: Principal Investigator  
Effort: 50%  
Total direct costs: \$80,000

Title: Predicting the Burden of Renal Disease after Liver Transplantation Using Simulation Allocation Model  
Funding Agency: Michigan Institute of Clinical and Health Research (NIH CTSA)  
Dates: 4/1/2009-3/31/2010  
Role: Principal Investigator  
Effort: 5%

Title: The GORE® VIATORR® TIPS Endoprosthesis versus Large-Volume Paracentesis for the Treatment of Ascites in Patients with Portal Hypertension (Site PI: Paula Novelli, MD)  
Funding Agency: W.L. Gore & Associates  
Dates: 4/1/11-12/31/12  
Role: Co-Investigator  
Effort: 1%  
Total Cost: \$40,477  
Total direct costs: \$50,000

Title: Hospitalization rates among post-liver transplant recipients  
Funding Agency: American College of Gastroenterology  
Start Date: 7/1/2012-6/30/2014  
Role: Principal Investigator  
Effort: 0%  
Total cost: \$ 35,000

Title: Predicting the burden of renal disease among liver transplant recipients  
Funding Agency: K08-National Institute of Diabetes Digestive and Kidney Diseases (DK-088946)  
Start Dates: 6/1/2011 – 4/30/2017  
Role: Principal Investigator

Effort: 75%  
Total cost: \$ 765,372

Title: Survival Benefit of Simultaneous Liver and Kidney Transplantation  
Funding Agency: MCUBE: University of Michigan  
Start Date: 1/1/2013-12/31/2014  
Role: Principal Investigator  
Effort: 0%  
Total cost: \$ 60,000

Title: A Multi-Center, Double-Blind, Randomized, Controlled Study to Determine the Safety and Pharmacokinetics of CP-1101 in Hepatorenal Syndrome  
Funding Agency: Cumberland Pharmaceutical Inc.  
Start Dates: 2/1/12-6/30/15  
Role: Site Principal Investigator  
Effort: 3%  
Total Cost: \$ 100,000

Title: Glycoproteomic biomarkers of Chronic Kidney Disease among liver transplant recipients  
Funding agency: University of Michigan George M O'Brien Renal Core Center  
Start Date: 9/2016-8/2017  
Role: Principal Investigator  
Effort: 0%  
Cost: \$5000

## Honors and Awards

### *Institutional*

1988 Certificate of Merit for getting Honors in Anatomy, University College of Medical Sciences, New Delhi, India  
1988 Silver medal for standing second in the First Professional Examination, MBBS, University College of Medical Sciences, New Delhi, India  
1993 Best Resident, Lady Hardinge Medical College, New Delhi, India  
2005 Excellence in patient care, Emory Transplant Center, Atlanta, GA  
2014 UM-IHPI RO1 boot camp

### *National*

2007 Young Investigator Award, American Society of Transplantation  
2008 Clinical Science Faculty Development Award in Liver Transplantation Outcomes, American Society of Transplantation  
2012 Research Award, American College of Gastroenterology

## Memberships in Professional Societies

### Professional Societies

7/05-Present American Association for the Study of Liver Diseases (AASLD)  
American Society of Transplantation (AST)

American Gastroenterology Association (AGA)  
American College of Gastroenterology (ACG)  
9/09-Present American Society of Transplantation Surgery (ASTS)

## **Editorial Positions, Boards and Peer-Review Service**

### Study Section/Advisory Panels:

#### *National*

2011 Co-chair, Student Mentored Grants, ASTS Grants Committee  
2012 Co-chair, Student Mentored Grants, ASTS Grants Committee  
2013 Co-chair, ASTS Faculty Development Award  
2015 Research scholar, AGA Research committee  
2016 Chair, Student research award, AGA Research committee  
2017 Student research award, AGA Research Committee

#### *International*

2011 Swiss National Science Foundation – Expert Grant Reviewer  
2012 Novartis Pharmaceuticals Zortess Advisory Board (3/8/12-3/9/12)  
2013 Austrian National Science Foundation – Expert Grant Reviewer

#### *Institutional*

2015 UM Study section: Joint Institution: University of Michigan and Peking University Health Science Center, Beijing, China  
2016 UM Study section: Joint Institution: University of Michigan and Peking University Health Science Center, Beijing, China

### Editorial Board:

2016- Member, Editorial board, Liver Transplantation,  
2012-2015 Contributor, Selected Summary, Gastroenterology contributor

### Manuscript Reviews

1999 *Kidney and Blood Pressure Research*  
2003 - *Digestive Diseases and Science*  
2007- *Liver Transplantation*  
2010 *Hepatology*  
2010- *American Journal of Gastroenterology*  
2011- *American Journal of Transplantation*  
2012- *Gastroenterology*  
2013- *Journal of American Society of Nephrology*  
2014- *New England Journal of Medicine*

### Abstract Review Committee

2017 Abstract reviewer for ACG  
2009-2016 Abstract reviewer for ATC  
2012 Abstract reviewer for ACG

## Teaching

Please refer to Educator's portfolio

## Committees, Organizational and Volunteer Service

### Institutional:

#### *Emory University School of Medicine*

- 8/03- 6/05 Research Committee, Emory Hospital Medicine Unit
- 1/04-6/05 Liver Leadership, Emory University Hospital
- 1/04-6/05 Liver Transplant Selection Committee, Emory University Hospital
- 6/04-6/05 Performance Improvement Clinical Committee (Liver Transplantation), Emory University Hospital

#### *University of Michigan*

- 2008 – Multidisciplinary Liver Transplant Selection Committee
- 2013- Multidisciplinary Prehab Committee for Liver Transplantation
- 2013- Education Committee, Transplant Hepatology Fellowship program
- 2014- Multidisciplinary Medication Compliance Task Force- Liver Transplantation
- 2014- Chair, Clinical Competency Committee, Transplant Hepatology Fellowship
- 2014- Lead, Renal Sparing Immunosuppression for Liver Transplant Recipients Task force
- 2016- Core faculty, GI clinical research curriculum development committee

### National:

- 12/09 Abstract Reviewer Committee for Clinical: Liver - Complications, Recurrent Disease, Hepatitis and Re-transplantation, American Transplant Congress (ATC), 2010
- 1/10-12/10 Committee member, Liver Transplantation and Surgery AASLD
- 5/10- 6/13 Grants Committee member, ASTS
- 12/10 Abstract Reviewer Committee for Clinical: Liver - Complications, Recurrent Disease, Hepatitis and Re-transplantation, ATC, 2011
- 3/11 Co-chair, Genentech Presidential Student Mentor Grant (ASTS)
- 5/11 Moderator: Clinical Effectiveness in Liver Disease, Research Forum at Digestive Disease Week 2011, Chicago, IL from 5/7/11-5/10/11 (5/8/11 from 4.00-5.30 PM)
- 12/11 Abstract Reviewer Committee for Clinical: Liver - Complications, Recurrent Disease, Hepatitis and Re-transplantation. ATC, 2012
- 6/12 Abstract Reviewer Committee for Clinical: Liver - Complications, Recurrent Disease, Hepatitis and Re-transplantation, ACG, 2012
- 12/12 Abstract Reviewer Committee for Clinical: Renal complication after Liver Transplantation, ATC, 2013
- 2013 Co-chair ASTS Faculty Development Award
- 6/2014- Research Awards Panel Committee, AGA
- 12/2014 Abstract Reviewer Committee for Clinical: Renal complication after Liver Transplantation, ATC, 2015
- 12/2015 Abstract Reviewer Committee for Clinical: Viral hepatitis after Liver Transplantation, ATC, 2016
- 2016-19 Research Committee, American College of Gastroenterology

## Visiting Professorships, Seminars and Extramural Invited Presentations

### *Visiting Professorships*

1. Visiting professorship at Transplant Grand Rounds at University of Utah on 12/19/07 'Liver allocation-Past, present and future'
2. Visiting Professor at University of Maryland, Baltimore on March 2012. Transplant Research Seminar Series: Renal disease before and after liver transplantation
3. Visiting Professor at All India Institute of Medical Sciences, New Delhi, India on 3/24/2014: 'Renal dysfunction and cirrhosis'.
4. Visiting Professor at Emory University, Atlanta, GA (10/28/14-10/29/14): Liver Allocation and Renal Function.

### *Continuing Medical Education:*

5. CME course: Invited talk for Advanced Liver Disease and Liver Transplantation Update, 2009 course on 5/1/09, University of Michigan: 'Optimizing Renal Function in Cirrhosis'
6. Transplant Nurses CME: University of Michigan on 10/6/09 'Renal Function in Cirrhosis: An Act of Balancing'
7. CME course: Invited talk for Advanced Liver Disease and Liver Transplantation Update, 2010 CME course on 5/14/10, University of Michigan: Immunosuppression: Generics vs. Brand
8. CME course: Invited talk for Advanced Liver Disease and Liver Transplantation Update, 2012 CME course on 5/4/12, University of Michigan: Liver Allocation: Present and Future
9. CME course: Invited talk for AASLD Wrap up, 2012 CME course on 12/8/12 held at Novi, MI, University of Michigan: 'Complications of Portal Hypertension'
10. CME Course: 'Annual Western Michigan Liver Round Up' 2014, CME course on 10/18/2014 held at Grand Rapids, MI: 'General Medical Care of Liver Transplant Patient'.
11. CME Course: Invited talk for 'Advanced Liver Disease and Transplantation' CME course: Nutritional issues in Cirrhosis' University of Michigan, Novi, MI. May 6<sup>th</sup>, 2016
12. American Liver Foundation sponsored CME, March 30<sup>th</sup>, 2017, Ann Arbor, MI: Speaker: Complications of Portal Hypertension

### *Seminars:*

13. American Gastroenterology Association-American Association for the Study of Liver Diseases: Academic skills workshop 2009 (3/13/09-3/14/09)
14. Rising Stars- Rising Stars Scientific Exchange at DDW, May 19<sup>th</sup>, 2012, San Diego, CA
15. Midday Symposium: American Transplant Congress' 2015 at Philadelphia, PA: 'Criteria for Simultaneous Liver-Kidney Transplant', Role: Presenter on May 5<sup>th</sup>, 2015 at 11.15AM - 12.45PM.
16. Clinical Symposium: Digestive Disease Week' 2015 at Washington D.C. 'Diagnosing and Treating Renal Disease in Cirrhotic Patients' on May 19<sup>th</sup> 2015 at 8.00 AM-9.30 AM
17. CRIC data Workshop: Limited competition NIH, Bethesda, MD July 29-July 30, 2015.
18. American Liver Foundation sponsored CME, March 30<sup>th</sup>, 2017, Ann Arbor, MI: Speaker: Complications of Portal Hypertension
19. Pre-meeting Symposium: Preserving Renal Function after Liver Transplantation at American Transplant Congress, 2017 at Chicago, IL; Role: Moderator



20. Pre-meeting Symposium: Preserving Renal Function after Liver Transplantation at American Transplant Congress, 2017 at Chicago, IL; Role: Presenter: “Early nephro-protective strategies after liver transplantation”.

*Intramural:*

1. GI Grand rounds, University of Michigan on 6/16/09 ‘Evidence-based Evolution of Liver Allocation Policy’
2. GI Research Rounds, University of Michigan on 1/25/10 ‘Liver Transplantation Outcomes’
3. GI Clinical Research conference, University of Michigan on 12/7/11 ‘Writing a Winning Abstract’
4. Transplant research Grand Rounds, University of Michigan Transplant Center on 1/16/12. Renal Disease among Liver Transplant Recipients
5. Renal Grand Rounds, University of Michigan, Nephrology Division on 10/3/12 “Renal dysfunction before and after liver transplantation”
6. Transplant Grand Rounds, University of Michigan, Transplantation Surgery on 7/15/13 “Everolimus for liver transplantation-Is it ready for prime time?”
7. Transplant Grand Rounds, University of Michigan, Transplantation Surgery on 1/13/14 “Simultaneous Liver and Kidney Transplantation”

**Bibliography** (*Peer Reviewed Publication*)

1. Singhal P, **Sharma P**, Garg P. Macrophage-HIV-1 gp160 protein interaction modulates mesangial cell proliferation and matrix synthesis. *American Journal of Pathology*, 1995; 147(6):1780-89: PMID: 7495302
2. **Sharma P**, Reddy K, Frankie N, Gibbons N, Sankaran RT, Ahuja TJ, Mattana J Singhal PC. Native and oxidized Low-density lipoproteins enhance mesangial cell apoptosis. *Kidney International*, 1996; 50:1604-1611: PMID: 8914027
3. Singhal PC, Shan Z, Garg P, Sharma K, **Sharma P**, Gibbons N. Morphine modulates migration of monocytes. *Nephron*, 1996; 73:526-531: PMID: 8856246
4. Singhal P, **Sharma P**, Singhal M, Gibbons N, Kapasi A, Reddy K. HIV- 1 gp 160 protein modulates proximal tubular cell proliferation and matrix synthesis. *Cell Physiology and Biochemistry*, 1997;7: 43-52:
5. Singhal P, **Sharma P**, Reddy K, Sanwal V, Rawal J, Gibbons N, Franki N. HIV- 1 gp 160 envelope protein modulates proliferation and apoptosis in mesangial cells. *Nephron*, 1997; 76:284-95: PMID: 9226228
6. Singhal P, **Sharma P**, Gibbons N, Franki N, Kapasi A Wagner J. Effect of morphine on reno medullary interstitial cell proliferation and matrix accumulation. *Nephron*, 1997;77:225- 234: PMID: 9346391
7. Singhal PC, Sagar P, Gupta S, Parsad A, **Sharma P**, Mattana J. Pressure modulates monocyte migration. *American Journal of Hypertension*, 1997;10:1297-1301: PMID: 9397250
8. Singhal PC, **Sharma P**, Sanwal V, Prasad A, Kapasi A, Ranjan R, Franki N, Reddy K Gibbons N. Morphine modulates proliferation of kidney fibroblasts. *Kidney International*, 1998; 53: 350-357: PMID: 9461094
9. Singhal PC, **Sharma P**, Loona R, Gibbons N, Franki N, Klotman PE. Enhanced proliferation, apoptosis and matrix accumulation by mesangial cells derived from HIV-1 transgenic mice. *Journal of Investigative Medicine*, 1998 Aug; 46(6);297-302: PMID: 9737092
10. Mattana J, Margiloff L, **Sharma P**, Singhal PC. Oxidation of the mesangial matrix metalloproteinase -2 impairs gelatinolytic activity. *Inflammation*, 1998;22(3):269-276: PMID:

9604714

11. Singhal PC, Gupta S, **Sharma P**, Shah H, Shah N, Patel P. Receptor mediated endocytosis by mesangial cells modulates transmigration of macrophages. *Inflammation*, 2000; 24(6):519 -532: PMID: 11128050
12. **Sharma P**, Perri RE, Sirven JE, Zeldenrust ZR, Brandhagen DJ, Rosen CB, Douglas DD, Mulligan DC, Rakela J, Wiesner RH, Balan V. Outcome of Liver transplantation for Familial Amyloidotic Polyneuropathy. *Liver Transplantation*, 2003, 9(12); 1273-1280: PMID: 14625827
13. Rodriguez-Luna H, Khatib A, **Sharma P**, De Petris G, Ortiz J, Hansen K, Mulligan D, Moss A, Douglas D, Balan V, Rakela J, Vargas HE. Treatment of recurrent hepatitis C infection after liver transplant with combination of PEG-IFN – 2b and ribavarin: An open label series. *Transplantation*, 2004,77(2);190-194: PMID: 14742979
14. Rodriguez-Luna H, Vargas HE, **Sharma P**, Ortiz J, De Petris G, Balan V, Byrne T, Moss A, Mulligan D, Rakela J, Douglas D. Hepatitis C virus recurrence in living related donor transplant recipients. *Digestive Disease and Sciences*, 2004, 49(1);38-41: PMID: 14992432
15. Rodriguez-Luna H, Balan V, **Sharma P**, Byrne T, Rakela J, argas HE. Hepatitis C virus infection with hepatocellular carcinoma, not a controversial indication for liver transplantation. *Transplantation*, 2004;78(4):580-583: PMID: 15446318
16. **Sharma P**, Balan V, Hernandez J, Rodriguez-Luna H, Rosati M, Schwartz J, Williams J, Douglas D, Harrison ME, Anderson M, Byrne T, Laskus T, Vargas HE, Rakela J. Hepatic steatosis in HCV genotype 3: Does it correlate with body mass index, fibrosis and HCV risk factors? *Digestive Disease and Sciences*, 2004, 49(1);25-29: PMID: 14992430
17. **Sharma P**, Balan V, Hernandez JL, Harper A, Edwards E, Rodriguez-Luna H, Byrne T, Vargas H, Douglas D, Mulligan D, Moss A, Rakela J, Wiesner RH. Liver transplantation for hepatocellular carcinoma: The MELD impact. *Liver Transplantation*,2004,10(1);36-41: PMID: 14755775
18. **Sharma P**, Rakela J. Management of pre liver transplant patients, Part 2, *CAQ corner, Liver Transplantation March 2005*;11(3):124-132 (Peer reviewed review): PMID: 15719412
19. **Sharma P**, Rakela J. Management of pre liver transplant patients, Part 1, *CAQ corner, Liver Transplantation February 2005*;11(2):124-132 (Peer reviewed review): PMID: 15666386
20. Sachdev M, Hernandez JL, **Sharma P**, Douglas DD, Byrne T, Harrison ME, Mulligan D, Moss A, Reddy K, Vargas HE, Rakela J, Balan V. Liver transplantation in the MELD era: A single-center experience. *Digestive Diseases and Sciences* 2006; 51(6):1070-1078: PMID: 16865573
21. **Sharma P**, Lok AS. Viral hepatitis and Liver transplantation. *Seminars in Liver Disease* 2006; 26:285-297 (Peer reviewed review): PMID: 16850378
22. **Sharma P**, Harper A, Hernandez JL, Heffron T, Mulligan D, Wiesner R and Balan V. Reduction in priority MELD score for hepatocellular carcinoma does not adversely impact candidate survival awaiting liver transplantation. *American Journal of Transplantation*, 2006; 6(8):1957-1962: PMID: 16771808
23. **Sharma P**, Marrero J, Fontana R, Greenon J, Conjeevaram H, Su GL, Askari F, Sullivan P and Lok AS. Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence. *Liver Transplantation*, 2007, 13(8)1100-1108: PMID: 17377914
24. Rubenstein JH, Saini SD, Kuhn L, McMahon L, **Sharma P**, Pardi DS, Schoenfeld P. Influence of malpractice history on the practice of screening and surveillance for Barrett's esophagus. *American Journal of Gastroenterology*, 2008,103(4):842-9: PMID: 18076733

25. **Sharma P**, Schaubel DE, Sima C, Goodrich N, Merion RM, Lok AS. Re-weighting the Model for End Stage Liver Disease score components. *Gastroenterology*, 2008; 135: 1575-1581: PMID: 18835388
26. Schaubel DE, Guidinger M, Biggins SW, Kalbfleisch J, Pomfret EA, **Sharma P**, Merion RM. Survival Benefit-Based Deceased-Donor Liver Allocation. *American Journal of Transplantation*, 2009, 9(4p2); 970-981: PMID: 19341419
27. **Sharma P**, Welch K, Eikstadt R, Marrero JA, Fontana RJ, Lok AS. Renal outcomes after liver transplantation in MELD era. *Liver Transplantation*, 2009; 15(9);1142-1148: PMID: 19718633
28. **Sharma P**, Schaubel DE, Guidinger M, Merion RM. Effect of pre-liver transplant creatinine on survival benefit of liver transplantation. *Liver Transplantation* 2009; 15 (12); 1808-1813: PMID: 19938142
29. **Sharma P**, Saini SD, Kuhn LB, Rubenstein JH, Pardi DS, Marrero JS, Schoenfeld PS. Knowledge of Hepatocellular Carcinoma Screening Guidelines and Clinical Practices among Gastroenterologists. *Digestive Disease and Sciences* 2011; 56(2);569-577: PMID: 20978844
30. Merion RM, **Sharma P**, Mathur AK, Schaubel DE. Evidenced-Based Development of Liver Allocation: A review. *Transplantation International* 2011; 24(10):965-72: PMID: 21615548
31. **Sharma P**, Schaubel DE, Guidinger MK, Ojo A, Merion RM. Impact of MELD-Based Liver Transplantation Allocation Policy on Post-Transplant End Stage Renal Disease. *American Journal of Transplantation*, 2011, 11(11):2372-78: PMID: 21883908
32. **Sharma P**, Lok AS. Interferon-Free Treatment Regimens for Hepatitis C: Are We There Yet? *Gastroenterology* 2011, 141(6);1963-1967. PMID: 23260492
33. **Sharma P**, Welch K, Hussain H, Pelletier SJ, Fontana RJ, Marrero JA, Merion RM. Incidence and Risk Factors of Hepatocellular Carcinoma Recurrence after Liver Transplantation in the MELD Era. *Digestive Disease and Sciences*, 2012, 57:806–812: PMID: 21953139
34. **Sharma P**, Schaubel DE, Gong Q, Guidinger MK, Merion RM. End-Stage Liver Disease Candidates at the Highest MELD Scores Have Higher Wait-list Mortality than Status-1A Candidates. *Hepatology*, 2012, 55 (1), 192-198: PMID: 21898487
35. Prabhu A, Dasika N, **Sharma P**. Upper GI Bleeding in a Post-Liver Transplant Patient. Clinical Challenge, *Gastroenterology* 2012, 142(7):1422-625. PMID: 22543112
36. **Sharma P**, Schaubel DE, Messersmith EE, Guidinger MK, Merion RM. Factors That Affect Deceased Donor Liver Transplantation Rates in the United States In Addition to Model for End Stage Liver Disease Score, *Liver Transplantation*, 2012, 18(12):1456-1463. PMID: 22965903
37. Barman P, **Sharma P**. Everolimus for Liver Transplant Recipients: Is It Ready For Prime Time? *Gastroenterology*, 2013, 144 (2):459-461. PMID: 23260492
38. **Sharma P**, Goodrich NP, Zhang M, Schaubel DE, Merion RM Short-term Pre-Transplant Renal Replacement Therapy and Renal Non-Recovery after Liver Transplantation Alone. *Clinical Journal of American Society of Nephrology*, 2013, Jul;8(7):1135-42. PMID: 23449770
39. **Sharma P**, Hosmer A, Appelman H, Mckenna B, Jafri M, Sullivan P, Fontana R, Lok, A. Immunological dysfunction on antiviral therapy for post-liver transplantation hepatitis C is associated with poor graft survival. *Hepatology International*, 2013, 7:990-999. PMID: 25815091
40. **Sharma P**. Sofosbuvir-Based Antiviral Therapy for Treatment Naïve Hepatitis C Genotypes 1, 2, and 3. *Gastroenterology* 2013, Jul;145(1):245-7. PMID: 23721818
41. Shreiner A, Dasika N, **Sharma P**. Lower GI Bleeding in a Patient with cirrhosis and colorectal cancer. Clinical Challenge, *Gastroenterology* 2013, 145 (3) e3-e4. PMID: 23896370
42. **Sharma P**, Goodrich NP, Schaubel DE, Guidinger ME, Merion RM. Patient Specific Prediction of End Stage Renal Disease Risk. *JASN*, 2013, 24: 2045-2052. PMID: 24029423

43. Salgia R, Goodrich NP, Merion RM, **Sharma P**. Outcomes of Liver Transplantation for Portal-pulmonary Hypertension in Model for End-stage Liver Disease Era. *Digestive Disease and Sciences*, 2014. DOI: 10.1007/s10620-014-3065-y. PMID: 24557576
44. Barman P, **Sharma P**, Krishnamurthy V, Willatt J, McCurdy H, Moseley RH, Su GL. Predictors of mortality in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. *Digestive Disease and Sciences*, 2014. Nov;59(11):2821-5. PMID: 24973040
45. Bari K, **Sharma P**. Combination of Daclatasvir and Sofosbuvir for Hepatitis C Genotypes 1, 2, and 3. *Gastroenterology*. 2014 Aug;147(2):534-6. PMID: 24953626
46. **Sharma P**, Goodrich NP, Schaubel DE, Merion RM. Serum Sodium and Survival Benefit of Liver Transplantation. *Liver Transplantation*, 2015, Mar;21(3):308-13. PMID: 25504743
47. Yu J, Hosmer A, Parks T, Sonnenday CJ, **Sharma P**. Predictors of 30-day readmission after deceased donor liver transplantation. *Digestive Disease and Sciences*, 2015, 60(11): 3242-3247. PMID: 26123837
48. **Sharma P** and Bari K. Chronic Kidney Disease and Related Long-term Complications Following Liver Transplantation. *Advances in Chronic Kidney Disease*, 2015, 22(5):404-11. PMID: 26311603
49. Bari K and **Sharma P**. Impact of BMI on post-transplant outcomes reexamined. *Liver Transplantation*, 2015, 21(10):1238-40. PMID: 26264149
50. **Sharma P**, Shu X, Schaubel DE, Sung RS, Magee J. Propensity score-based Survival Benefit of Simultaneous Liver-Kidney Transplant over Liver Transplant Alone for Recipients with Renal Dysfunction. *Liver Transplantation*, 2016, Volume 22(1), Pages 71–79. PMID: 26069168
51. Levitsky J, Niemann N, Fung J, **Sharma P**, Asrani S, Wiseman A, O’Leary J. Protecting the Kidney in Liver Transplant Recipients. *American Journal of Transplantation*, 2016, Accepted for Publication. PMID: 26932352
52. Glass L, **Sharma P**. Evidence-based therapeutic options for hepatorenal syndrome. *Gastroenterology*, 2016, 2016 Apr;150(4):1031-3. PMID: 26922867
53. **Sharma P**, Parikh ND, Yu Jessica, Barman P, Derstine B, Sonnenday CJ, Wang S, Su GL. Bone Mineral Density Predicts Post-transplant Survival among Hepatocellular Carcinoma Liver Transplant Recipients. *Liver Transplantation*, 2016, Aug;22(8):1092-8. PMID: 27064263
54. Singal AG, Zhang P, Ananthakrishnan L, Waljee AK, Parikh N, **Sharma P**, Barman P, Krishnamurthy V, Wang L, Wang SC, Su GL. Body composition features predict overall survival in patients with hepatocellular carcinoma. *Clinical and Translational Gastroenterology*, 2016, *Clin Transl Gastroenterol*. 2016 May 26;7:e172. doi: 10.1038/ctg.2016.31. PMID: 27228403
55. Goodrich NP, Schaubel DE, Smith A, Merion RM, **Sharma P**. National assessment of hospitalization rates for incident end stage renal disease after liver transplantation. *Transplantation*, 2016, 100(10)2115-21. PMID: 27467539
56. Guivatchian T, Koeppe ES, Baker JR, Moisa C, Demerath M, Foor-Pessin C, Chey WD, Eswaran SL, Kolars JC, Menees SB, Rajala M, Rice MD, Rizk R, Rubenstein JH, **Sharma P**, Todisco A, Stoffel EM. Family History in Colonoscopy Patients: Feasibility and Performance of Electronic and Paper-based Surveys for Colorectal Cancer Risk Assessment in the Outpatient Setting. *Gastrointestinal Endoscopy*, 2017, doi: 10.1016/j.gie.2017.01.036
57. Konerman MA, Fritze D, Weinberg RL, Sonnenday CJ, **Sharma P**. Incidence of and Risk Assessment for Adverse Cardiovascular Outcomes Following Post Liver Transplantation: A Systematic Review. *Transplantation* 2017, accepted for publication
58. **Sharma P**, Goodrich NP, Schaubel DE, Smith A, Merion RM. National Assessment of Early Hospitalization after Liver Transplantation: Risk Factors and Association with Patient Survival. *Liver Transplantation*, 2017, accepted for publication.

### Book Chapters

1. **Sharma P**, Vargas H, Rakela J. Monitoring and care of the patients before transplant (2005) *Transplantation of the Liver*, 2<sup>nd</sup> edition, Editors Busuttil RW and Klintmalm GB, Publisher Elsevier Science
2. Bala V, **Sharma P**, Anania F. Cirrhosis and Liver Failure (2007) *Comprehensive Hospital Medicine*, Editors Williams M, Flanders S, Whitcomb W, Cohn S, Publisher Elsevier Science
3. Yu Jessica and **Sharma P**. Organ Allocation Policy: Practical issues and challenges to gastroenterologists. *Liver and Biliary Disease Section*, 2nd Edition, Editors: Lindor K and Bashar A, Publisher Wiley (2016)

### Other Media

1. **Sharma P** and Su GL: *American Gastroenterology Association (AGA) Gastroslides for Gastroenterology Teaching Project (2009)*. Liver Diseases and Gall Stones in Women, launched during DDW-2009. This slideset has 83 slides with notes and up to date references. The topics covered by me in this slideset are Hepatocellular Carcinoma, Benign Solid Lesions of Liver, Polycystic Liver Disease, Primary Biliary Cirrhosis and Gall stones (*original contribution*).
2. **Sharma P**: Contribution to *American Gastroenterology Association-Gastroenterology Self-Assessment Module* for GI board certification and re-certification on Women and Gastrointestinal Health-Liver (2010)
3. **Sharma P**: Ann Arbor VA SCAN project: Hepatorenal Syndrome: Educational Video talk for the community physicians (2011)
4. **Sharma P**: Contributor to DDSEP 6 launched at DDW'2013
5. **Sharma P** and Perlmutter A (2014): RRI Calculator: <https://rri.med.umich.edu>
6. **Sharma P**: Contributor to DDSEP 8 launched at DDW' 2016

### Abstracts: (out of 45)

1. **Sharma P**, Sankaran R, Ahuja T, Mattana J, Singhal P. Low density lipoproteins (LDL) enhance mesangial cell apoptosis. *Poster, American Society of Nephrology 1995, San Diego, J of Am. Soc. Nephrol, 1995;6(3):911*
2. Garg P, **Sharma P**, Mattana J, Singhal P. Angiotensin II modulates glomerular epithelial cell metalloproteinase activity. *Poster, FASEB' 95, Atlanta, FASEB Journal, 1995;9(4): A660*
3. **Sharma P**, Garg P, Arya M, Singhal P. Peripheral blood mononuclear cells and HIV - 1 gp160 envelope protein interaction modulates enhances matrix synthesis by mesangial cells. *Poster, FASEB' 95, Atlanta FASEB Journal, 1995;9(4):A974*
4. Singhal P, **Sharma P**, Reddy K, Ahuja T, Sankaran R, Gibbons N, Franki N. Simulated glomerular hypertension modulates apoptosis in glomerular endothelial cells. *Poster, FASEB'96 FASEB Journal 1996;10(3)A4*
5. **Sharma P**, Ahuja T, Sankaran R, Mattana J, Franki N, Singhal P. Applied pressure induces apoptosis in mesangial cells. *Poster, FASEB'96 FASEB Journal 1996; 10(3) A45*
6. Kaushik N, **Sharma P**, Singhal P. Street Heroin adulterants modulate mesangial cell proliferation. *Poster, FASEB'96 FASEB Journal 1996;10(3)A454.*
7. Singhal PC, **Sharma P**, Loona R, Gibbons N, Klotman P. Mesangial cells (MC) derived from mice transgenic for HIV –I genes have enhanced proliferation, apoptosis and collagen. **Poster, American Society of Nephrology 1997 San Antonio, J of Am soc. Nephrol. Sept. 1997;9:508A**

8. **Sharma P**, Douglas D, Blair J, Balan V, Vargas H, Byrne T, Rakela J, Harrison M, Moss A, Mulligan D, The effect of anti-fungal prophylaxis on outcomes after adult living donor liver transplant. *American Transplant Congress, 2003 at Washington DC*
9. **Sharma P**, Balan V, Hernandez J, Rodriguez-Luna H, Douglas D, Vargas H, Rakela J, Wiesner R. Outcome of Liver Transplantation (LT) for familial amyloidotic neuropathy Type-I. *American Transplant Congress, 2003 at Washington DC*
10. **Sharma P**, Harper A, Hernandez J, Heffron T, Williams M, Mulligan D, Balan V. Liver transplantation for hepatocellular carcinoma: Reduction in priority MELD score does not adversely impact candidate survival awaiting liver transplant. *Late Breaking Poster AASLD, 2004, Boston, MA*
11. **Sharma P**, Marrero J, Fontana R, Conjeevaram H, Su GL, Askari F, Sullivan, P, Lok, AS. Sustained virologic response to treatment of recurrent hepatitis C after liver transplantation is related to actual dose of peginterferon and ribavirin received. *Digestive Diseases Week, 2006, Los Angeles, CA*
12. **Sharma P**, Schaubel DE, Sima C, Goodrich N, Merion R, Lok A. Serum creatinine is overweighted in existing MELD formula. *American Transplant Congress, 2007, San Francisco, CA*
13. **Sharma P**, Saini S, Bernard L, Rubenstein, JL, Pardi D, Marrero J, Schoenfeld P. Knowledge of Hepatocellular Carcinoma Surveillance Guidelines and Current Practices: Results of a National survey. *American College of Gastroenterology National Meeting, 2007, Philadelphia, PA*
14. **Sharma P**, Schaubel DE, Guidinger M, Merion R. Effect of pre-liver transplant creatinine on survival benefit of liver transplantation. *American Transplant Congress, 2008, Toronto, ON, Canada*
15. **Sharma P**, Welch K, Eickstadt R, Marrero J, Fontana R, Lok A. Effect of pre-liver transplantation renal function on outcomes after liver transplantation in the MELD Era. *American Association of Study of Liver Diseases, 2008, San Francisco, CA*
16. **Sharma P**, Schaubel DE, Gong Qi, Guidinger MK, Merion RM. End stage liver disease patients with high MELD have higher wait list mortality than Status-1 patients. *American Transplant Congress, 2009, Boston, MA*
17. **Sharma P**, Byrne T, Welch K, Vargas H, Marrero JA, Merion R. Hepatocellular Carcinoma-Recurrence Risk Index May Predict Post-Transplant Hepatocellular Carcinoma Recurrence Better Than Milan Criteria. *American Transplant Congress, 2010, San Diego, CA*
18. **Sharma P**, Pelletier S, Hussain H, Fontana RJ, Marrero JA, Merion RM. Incidence and Pre-Transplant Risk Factors of Hepatocellular Carcinoma Recurrence after Liver Transplantation in MELD Era. *American Transplant Congress, 2010, San Diego, CA*
19. **Sharma P**, Schaubel DE, Messersmith E, Guidinger MK, Merion RM. Factors Other Than MELD That Determine Deceased Donor Liver Transplantation Rates. *American Transplant Congress, 2010, San Diego, CA*
20. **Sharma P**, Schaubel DE, Guidinger MK, Ojo A, Merion RM. Impact of MELD-Based Liver Transplantation Allocation Policy on Post-Transplant End Stage Renal Disease. *American Transplant Congress, 2010, San Diego, CA*
21. **Sharma P**, Appelman H, Mckenna B, Jafri M, Sullivan P, Fontana R, Lok, A. Immunological dysfunction on antiviral therapy for post-liver transplantation hepatitis C is associated with poor graft survival. *American Transplant Congress, 2011, Philadelphia, PA*
22. **Sharma P**, Goodrich NP, Zhang M, Schaubel DE, Merion RM. Predictors of Renal Recovery After Liver Transplantation: Implications for Organ Allocation. Oral Presentation, *American Transplant Congress, 2012, Boston, MA*
23. **Sharma P**, Schaubel DE, Guidinger MK, Goodrich NP, Merion RM. Prediction of End Stage Renal Disease Risk after Liver Transplantation based upon Recipient factors. Oral Presentation, *American Transplant Congress, 2012, Boston, MA*



24. **Sharma P**, Schaubel DE, Goodrich NP, Merion RM. Effect of serum sodium on survival benefit of liver transplantation. *Oral Presentation, American Transplant Congress, 2013, Seattle, WA*
25. Salgia R, Goodrich NP, Merion RM, **Sharma P**. Favorable Post-Transplant Survival for Liver Transplant Recipients with Treated Porto-Pulmonary Hypertension. *Oral Presentation, American Transplant Congress, 2013, Seattle, WA*
26. **Sharma P**, Shu X, Schaubel DE, Sung RS, Magee J. Comprehensive Post-transplant Mortality Analysis: Simultaneous Liver and kidney transplant versus liver transplant alone recipients with pre-transplant Renal Dysfunction. *Poster Presentation, World Transplant Congress, 2014, San Francisco, CA*
27. Yu J, Hosmer A, Parks T, Sonnenday CJ, **Sharma P**. Predictors of 30-day readmission after deceased donor liver transplantation. *Poster presentation, AASLD 2014, Boston, MA*
28. Konerman M, Fritze D, Spengler E, Sonnenday CJ, **Sharma P**. Incidence of and Risk Assessment for Adverse Cardiovascular Outcomes Following Liver Transplantation: A Systematic Review. *Poster presentation, ATC 2016, Boston, MA*
29. Sun Y, Erley J, Shen J, Sonnenday CJ, **Sharma P**, Park J. Renal Risk Index and Acute Kidney Injury in Liver Transplant Patients. *Poster presentation, ATC 2016, Boston, MA*
30. Zee J, Bello GA, Oguntimein M, Beil C, Liu Q, Park J, Saulles AR, Goel S, Balkrishnan R, Fava M, Merion RM, Leichtman AB, **Sharma P**. Comparison of the effects of brand name versus generic immunosuppressant on long-term graft failure risk among U.S. liver transplant recipients: Analysis of SRTR and Medicare claims data. *Oral Presentation. International Meeting of the Transplantation Society. August 2016, Hong Kong, China*
31. **Sharma P**, Goodrich NP, Schaubel DE, Smith A, Merion RM. Burden of Early Hospitalization among Liver Transplant Recipients. *Poster presentation ATC 2017, Chicago, IL*
32. Liu Q, Smith A, Park J, Oguntimein M, Dutcher S, Bello G, Helmuth M, Turenne M, Balkrishnan R, fava M, **Sharma P**, Beil C, Leichtman A, Zee J. The Adoption of Generic Immunosuppressant Medications Among Kidney and Liver Transplant Recipients Using the Colorado All Payer Claims Database. *Poster presentation ATC 2017, Chicago, IL*
33. Park J, Koerschner C, Selman S, Mawby J, Paknikar S, Sonnendat CJ, Wright Nunes J, **Sharma P**. Knowledge of Chronic Kidney Disease among Liver Transplant Recipients. *Poster Presentation, ATC 2017, Chicago, IL*